$1.30
8.45% yesterday
Nasdaq, Jun 13, 10:17 pm CET
ISIN
US44148G1058
Symbol
HOTH
Sector
Industry

Hoth Therapeutics, Inc. Stock price

$1.30
+0.40 44.57% 1M
+0.49 60.49% 6M
+0.55 73.77% YTD
+0.34 35.19% 1Y
-66.45 98.08% 5Y
-211.95 99.39% 10Y
-211.95 99.39% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.12 8.45%
ISIN
US44148G1058
Symbol
HOTH
Sector
Industry

Key metrics

Market capitalization $17.17m
Enterprise Value $5.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.48
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-9.64m
Free Cash Flow (TTM) Free Cash Flow $-8.04m
Cash position $11.32m
EPS (TTM) EPS $-0.75
P/E forward negative
Short interest 0.43%
Show more

Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Hoth Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Hoth Therapeutics, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Hoth Therapeutics, Inc.:

Buy
100%

Financial data from Hoth Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.90 4.90
1% 1%
-
- Research and Development Expense 4.74 4.74
45% 45%
-
-9.63 -9.63
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.64 -9.64
28% 28%
-
Net Profit -9.62 -9.62
25% 25%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hoth Therapeutics, Inc. Stock News

Neutral
PRNewsWire
2 days ago
Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK , June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No.
Neutral
PRNewsWire
3 days ago
Premier Research to support submission of an Expanded Access Program (EAP) application. This move positions Hoth to offer compassionate access to HT-001 for cancer patients suffering from painful and debilitating skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitor therapies—an area of high unmet medical need.
Neutral
PRNewsWire
9 days ago
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK , June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event ...
More Hoth Therapeutics, Inc. News

Company Profile

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

Head office United States
CEO Robbie Knie
Employees 3
Founded 2017
Website hoththerapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today